- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05076071
Clinical Value of Next Generation Sequencing in Chinese Childhood Solid Tumors
Clinical Value of Next Generation Sequencing in Chinese Childhood Solid Tumors: A Multicenter Study
Study Overview
Detailed Description
DNA and RNA extracted from tumor tissues and leukocytes will be analyzed by Onco PanScan/whole exon sequencing(Genetronhealth), and comprehensive gene mutation information such as single nucleotide variation, insertion deletion mutation, gene copy number variants and structure variants will be obtained.
Through in-depth mining of genomic data generated by clinical tumor tissue detection, the differences among different subtypes of pediatric solid tumors in TCGA data will be compared with previous studies. Combined with clinical pathological and molecular subtyping results, auxiliary diagnosis was performed. Analyzing therapeutic targets and identifying pathogenic cancer-predisposing variants may provide molecular reference for children's malignant solid tumors.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: suying lu
- Phone Number: +8613570435681
- Email: lusy@sysucc.org.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Recruiting
- Sun Yat-sen University Cancer Center
-
Contact:
- Yi-Zhuo Zhang, MD
- Phone Number: 18622221239
- Email: zhangyzh@sysucc.org.cn
-
Principal Investigator:
- Yi-Zhuo Zhang, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients are diagnosed by histology and pathology as pediatric malignant solid tumors (including soft tissue sarcoma, osteosarcoma, pediatric glioma, neuroblastoma, nephroblastoma, retinoblastoma, hepatoblastoma, atypical teratoid/rhabdomymoma, embryonal tumor, etc.);
- Age: < 18 years old;
- Eastern Cooperative Oncology Group (ECOG) PS score: 0-2, estimated survival >6 months;
- Complete clinical laboratory examination and pathological examination information of patients;
- Patients can be evaluated on time, and samples can be obtained throughout the whole test process;
- Informed consent signed by the patient or his/her legal representative shall be obtained after the patient is informed of the project;
Exclusion Criteria:
- As determined by the investigator, the patient had other major diseases that might affect follow-up and short-term survival;
- Any social/psychological problems that the researcher determines are not suitable for the study;
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mutation characteristics of malignant solid tumors in Chinese children.
Time Frame: 2021.8-2023.8
|
2021.8-2023.8
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SunYat-sen U
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric, Solid Tumors, NGS
-
Memorial Sloan Kettering Cancer CenterMerck Sharp & Dohme LLCActive, not recruitingSolid Tumors | Identified by NGS, PCR or IHCUnited States
-
University Hospital, Strasbourg, FranceRecruitingPediatric Solid TumorsFrance
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Bristol-Myers SquibbCompleted
-
National Council of Scientific and Technical Research...RecruitingPediatric Solid TumorsArgentina
-
Memorial Sloan Kettering Cancer CenterCompletedPediatric Patients With Solid TumorsUnited States
-
Washington University School of MedicineWithdrawn
-
Memorial Sloan Kettering Cancer CenterPfizer; University of Wisconsin, Madison; Duke University; AEterna Zentaris; NATL...CompletedPediatric Solid TumorsUnited States
-
St. Jude Children's Research HospitalAlex's Lemonade Stand FoundationRecruiting
-
Samsung Medical CenterMinistry of Health, Republic of KoreaNot yet recruitingRelapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
Clinical Trials on NGS
-
Shanghai Children's HospitalChildren's Hospital affiliated to Chongqing Medical University; Xuzhou maternal...Not yet recruitingPremature Infants | NICU Infants | Conventional NBS-positive Infants
-
Chang Gung Memorial HospitalRecruitingRecurrent Miscarriage | Chromosome Translocation | Genetic Disorders in PregnancyTaiwan
-
Rennes University HospitalCompleted
-
Shanghai Children's HospitalChildren's Hospital of Chongqing Medical University; Northwest Women's and... and other collaboratorsNot yet recruiting
-
Karolinska University HospitalCompletedPancreatic Ductal Adenocarcinoma
-
National Cancer Institute (NCI)RecruitingAcute Lymphoblastic Leukemia | B-AllUnited States
-
The Belgian Society of Medical OncologyRoche Pharma AG; Foundation Medicine; SciensanoRecruiting
-
Xianmin Song, MDRecruiting
-
Chinese Anti-Cancer AssociationUnknown
-
National Cancer Institute, NaplesRecruiting